Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?

[1]  Huiyan Jiang,et al.  Basic Pancreatic Lesions: Radiologic-pathologic Correlation , 2022, Journal of translational internal medicine.

[2]  A. Zwinderman,et al.  Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  T. Desser,et al.  Imaging Assessment of Pancreatic Cancer Resectability after Neoadjuvant Therapy: AJR Expert Panel Narrative Review. , 2021, AJR. American journal of roentgenology.

[5]  N. Petrucciani,et al.  Neoadjuvant therapy for pancreatic cancer , 2021, Updates in Surgery.

[6]  E. O’Reilly,et al.  Pancreatic Cancer: A Review. , 2021, JAMA.

[7]  Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[8]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  Yun Bian,et al.  The relationship between microscopic tumor size and CT tumor size in pancreatic ductal adenocarcinoma. , 2020, Clinical imaging.

[11]  A. Zwinderman,et al.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Naveen M. Kulkarni,et al.  White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology’s disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease , 2019, Abdominal Radiology.

[13]  Yun Bian,et al.  Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens , 2019, Abdominal Radiology.

[14]  Anas M. Saad,et al.  Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study , 2018, BMC cancer.

[15]  V. Torri,et al.  Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. , 2018, The lancet. Gastroenterology & hepatology.

[16]  G. Tienhoven,et al.  Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer , 2018, The British journal of surgery.

[17]  N. Pavlakis,et al.  Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data , 2018, ANZ journal of surgery.

[18]  H. Lang,et al.  Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits , 2017, International journal of molecular sciences.

[19]  T. Ohtsuka,et al.  Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis , 2017, Pancreas.

[20]  J. Berlin,et al.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Winter,et al.  Pancreatic Cancer: A Review. , 2016, Gastroenterology clinics of North America.

[22]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[23]  Kelley Tipton,et al.  Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma , 2014 .

[24]  Arif N Ali,et al.  Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. , 2012, International journal of radiation oncology, biology, physics.

[25]  Huamin Wang,et al.  Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis. , 2012, Annals of diagnostic pathology.

[26]  C. Verbeke,et al.  Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment * , 2011, Histopathology.

[27]  A. Niemierko,et al.  Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. , 2011, International journal of radiation oncology, biology, physics.

[28]  Wendy Frankel,et al.  Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum. , 2008, Archives of pathology & laboratory medicine.

[29]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[30]  E. Paulson,et al.  Staging of pancreatic cancer before and after neoadjuvant chemoradiation , 2001, Journal of Gastrointestinal Surgery.

[31]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[32]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[33]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .